secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001213900-24-066641
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue $18.8M (+36% YoY); GAAP EPS loss $(0.22); guides FY rev >=$100M
--------------------------------------------------------------------------------

- Revenue $18.8M (+36% YoY); gross profit $11.7M (+50%); gross margin 62%.
- GAAP net loss $(4.0M) ($(0.22)/share); non-GAAP net income $0.3M ($0.02/diluted).
- Adjusted EBITDA $0.5M vs $(0.8M) prior year; FY2024 guidance reaffirmed: rev >=$100M, Adj EBITDA >=$11M.
- CEO cites ~$6M DAAP program delayed from Q2; without delay would have exceeded consensus.
- KPIs: avg rev per top 20 pharma $2.7M (up from $1.8M); net revenue retention 124% (vs 89%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/0001213900-24-066641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/ea0210870-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-066641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer